## Abstract The promising drug candidate indazolium __trans__‐[tetrachlorobis(1__H__‐indazole)ruthenate(III)] (KP1019) is the second Ru‐based anticancer agent to enter clinical trials. In this review, which is an update of a paper from 2006 (__Hartinger et al., J. Inorg. Biochem.__ **2006**, __100_
✦ LIBER ✦
Development of 17α-Estradiol as a Neuroprotective Therapeutic Agent: Rationale and Results from a Phase I Clinical Study
✍ Scribed by JAMES A. DYKENS; WALTER H. MOOS; NEIL HOWELL
- Book ID
- 111479383
- Publisher
- John Wiley and Sons
- Year
- 2005
- Tongue
- English
- Weight
- 801 KB
- Volume
- 1052
- Category
- Article
- ISSN
- 0890-6564
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
KP1019, A New Redox-Active Anticancer Ag
✍
Christian G. Hartinger; Michael A. Jakupec; Stefanie Zorbas-Seifried; Michael Gr
📂
Article
📅
2008
🏛
John Wiley and Sons
🌐
English
⚖ 347 KB
👁 1 views
ChemInform Abstract: KP1019, A New Redox
✍
Christian G. Hartinger; Michael A. Jakupec; Stefanie Zorbas-Seifried; Michael Gr
📂
Article
📅
2009
🏛
John Wiley and Sons
⚖ 16 KB
👁 1 views
## Abstract ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable v
A National Survey of Simulation Prevalen
✍
Jennifer Hayden
📂
Article
📅
2011
🏛
Elsevier
🌐
English
⚖ 48 KB
34 The TGF-beta2 antisense ollgonucleoti
✍
P. Hau; U. Bogdahn; J. Schlaier; M. Mehdorn; G. Wurm; J. Pichier; M. Kunst; M. G
📂
Article
📅
2003
🏛
Elsevier Science
🌐
English
⚖ 169 KB